Gemini Therapeutics (GMTX) Competitors $59.75 +1.03 (+1.75%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation. Is BBIO or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% Gemini Therapeutics N/A -38.78%-35.88% Does the media prefer BBIO or GMTX? In the previous week, BridgeBio Pharma had 16 more articles in the media than Gemini Therapeutics. MarketBeat recorded 16 mentions for BridgeBio Pharma and 0 mentions for Gemini Therapeutics. BridgeBio Pharma's average media sentiment score of 0.72 beat Gemini Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Overall Sentiment BridgeBio Pharma Positive Gemini Therapeutics Neutral Which has more risk and volatility, BBIO or GMTX? BridgeBio Pharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Which has preferable earnings & valuation, BBIO or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$235.81M39.79-$535.76M-$4.09-12.00Gemini TherapeuticsN/AN/A-$71.87M-$1.00-59.75 Do analysts recommend BBIO or GMTX? BridgeBio Pharma presently has a consensus target price of $61.35, indicating a potential upside of 25.01%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in BBIO or GMTX? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryBridgeBio Pharma beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$832.55M$5.76B$9.61BDividend YieldN/A4.84%4.41%4.10%P/E Ratio-59.751.1731.1026.04Price / SalesN/A26.34435.05103.72Price / CashN/A19.5637.7358.48Price / Book20.676.659.536.61Net Income-$71.87M-$4.94M$3.26B$265.56M7 Day Performance-0.18%1.08%2.10%1.95%1 Month Performance-1.63%2.03%2.82%-0.37%1 Year Performance22.56%10.56%30.56%19.02% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$59.75+1.8%N/A+22.6%$2.59BN/A-59.7530BBIOBridgeBio Pharma4.6814 of 5 stars$49.02-4.5%$61.35+25.2%+97.2%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4117 of 5 stars$105.79+0.5%$109.00+3.0%+290.2%$8.96B$42.28M-106.8630Short Interest ↓ELANElanco Animal Health3.0897 of 5 stars$17.72-1.4%$17.33-2.2%+22.4%$8.92B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.4818 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4381 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Insider TradeGRFSGrifols3.5781 of 5 stars$10.58-1.3%$10.30-2.6%+14.8%$7.37B$7.45B9.0423,822Short Interest ↑LEGNLegend Biotech3.797 of 5 stars$37.45-0.1%$72.38+93.3%-38.0%$6.89B$627.24M-42.562,609RVMDRevolution Medicines4.4106 of 5 stars$36.45+0.4%$69.54+90.8%-14.4%$6.79B$11.58M-8.10250News CoveragePositive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8274 of 5 stars$98.09+0.5%$101.57+3.5%+133.7%$6.48B$156.29M-32.59140News CoveragePositive NewsRNAAvidity Biosciences3.1843 of 5 stars$44.48-4.3%$67.00+50.6%+8.2%$5.98B$10.90M-12.49190Positive NewsInsider TradeOptions Volume Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access